Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Fig. 5

Changes of the immunopeptidome through trametinib treatment (30 nM for 48 h) in four PDOs. a Western blot showing inhibition of ERK phosphorylation (pERK) through trametinib. b Number of HLA-I molecules per cell with and without trametinib treatment. c Number of unique peptides presented on HLA-I with and without trametinib treatment. d Change in peptide diversity and HLA-I abundance with and without trametinib treatment. e Volcano plots showing the fold change of normalized peptide abundance with trametinib treatment. The dashed red lines indicate a q-value of 0.05 and vertical dashed lines fold changes exceeding +/− 2. f Number of unique peptides detected by MS on HLA-II molecules with and without trametinib treatment

Back to article page